Clinical Trials Offer Hope for the Future of Gynecologic Cancer Treatment 

Explore how groundbreaking clinical trials at Broward Health are transforming the treatment of advanced gynecologic cancers, offering new lifelines to patients in the fight for their lives. The health system is participating in clinical trials designed to provide new treatment options for patients with advanced and recurrent ovarian and endometrial cancer.

“At Broward Health, we are very passionate about gynecologic cancer research,” said Scott E. Jordan, M.D., FACOG, gynecologic oncologist with the Broward Health Physician Group. “We prioritize research in our practice model.”

The GLORIOSA Trial

The first trial, GLORIOSA, offers new maintenance therapy options for patients with recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer with high folate receptor-alpha expression.

“The world of ovarian cancer treatment is changing rapidly, and many former recurrence therapies are now first-line treatments, so we are working on new second-line options,” Dr. Jordan said. “We are hoping this trial will keep patients disease-free for as long as possible, and if they do experience a recurrence, they will hopefully respond better to chemotherapy.”

The Selinexor Trial

In the past two years, endometrial cancer treatment has changed completely.

“Where survival often used to be less than a year, we’re now seeing survival on the order of multiple years,” Dr. Jordan said. “Patients who we never thought would have a chance of cure now have a very realistic chance of cure.”

Around 40% of endometrial cancer patients have mismatch repair deficient tumors. Adding immunotherapy to chemotherapy in these patients has greatly improved survival.

But for the patients whose tumors are not mismatch repair deficient, advancing treatment has stalled.

“This new study is looking at selinexor as a maintenance therapy once patients have responded to standard of care chemotherapy in either the metastatic frontline setting or the first recurrence,” Dr. Jordan said. “If they have the p53 wild type biomarker, which around 50% of endometrial cancers do, preliminary data shows about a greater than two-year progression-free survival advantage with this drug.”

Gynecologic Cancers affect the female reproductive system.

– Cervical cancer

– Endometrial cancer

– Gestational trophoblastic disease

– Ovarian Cancer

– Uterine sarcoma

– Vaginal cancer

– Vulvar cancer